AbbVie Inc (ABBV)vsMeihua International Medical Technologies Co Ltd (MHUA)
ABBV
AbbVie Inc
$227.23
-2.14%
HEALTHCARE · Cap: $391.50B
MHUA
Meihua International Medical Technologies Co Ltd
$7.61
0.00%
HEALTHCARE · Cap: $425.43M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 70051% more annual revenue ($62.82B vs $89.55M). MHUA leads profitability with a 10.3% profit margin vs 5.8%. MHUA trades at a lower P/E of 0.3x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
MHUA
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$227.23
$81.01 premium
Intrinsic value data unavailable for MHUA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Revenue declined 16.2%
Earnings declined 42.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : MHUA
The strongest argument for MHUA centers on P/E Ratio, Price/Book, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : MHUA
The primary concerns for MHUA are Market Cap, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while MHUA is a declining play — different risk/reward profiles.
MHUA carries more volatility with a beta of 0.75 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 34/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Meihua International Medical Technologies Co Ltd
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Meihua International Medical Technologies Co., Ltd. is engaged in the manufacturing and marketing of medical consumables in the People's Republic of China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?